Tag: investors

Transparency Notification from Shareholders

WNC & Associates and Ravello Holdings continue partnership to meet urgent housing needs

OTTAWA, June 26, 2025 (GLOBE NEWSWIRE) -- Colonnade BridgePort, a leading full-service real estate investment, development, and management company, has officially broken ground on RYSE, a new purpose-built multi-residential development located at 1950 Scott Street in Ottawa’s Westboro neighbourhood. Designed to meet the growing demand for high-quality rental housing in one of the city’s most sought-after communities, RYSE will offer a modern living experience that emphasizes connectivity, livability, and convenience.

SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

Oeno Group recently celebrated its 10-year anniversary with an exclusive event for its clients.

Investors Rush as Neo Pepe’s Mind-blowing Stage 4 Presale Ignites

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp. (“the Company”) is pleased to announce it has completed the overnight offering of Preferred Shares and Class A Shares of the Company. Total gross proceeds of the offering were $40.0 million, bringing the Company’s net assets to approximately $217.9 million.

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.